Bladder cancer is a prevalent but currently understudied cancer type and patient outcomes are poor when it progresses to the muscle-invasive stage. Current research in bladder cancer focuses on the genetic and epigenetic alterations occurring within the urothelial cell compartment; however, the stromal compartment receives less attention. Dynamic changes and intercellular communications occur in the tumour microenvironment (TME) of the bladder — a new concept and niche that we designate as the bladder TME (bTME) — during tumour evolution, metastatic progression and in the context of therapeutic response. Collagens and their cognate receptors, the discoidin domain receptors, have a role in various steps of the metastatic cascade and in immune checkpoint resistance. Furthermore, the presence of another TME niche, the metastatic TME (met-TME), is a novel concept that could support divergent progression of metastatic colonization in different organs, resulting in distant metastases with distinct characteristics and genetics from the primary tumour. The stroma has divergent roles in mediating therapeutic response to BCG immunotherapy and immune checkpoint inhibitors, as well as conventional chemotherapy or trimodality therapy (that is, maximal transurethral resection of bladder tumour, chemotherapy and radiotherapy). The local bTME and distant met-TME are currently conceptually and therapeutically unexploited niches that should be actively investigated. New biological insights from these TMEs will enable rational design of strategies that co-target the tumour and stroma, which are expected to improve the outcomes of patients with advanced bladder cancer.
Your institute does not have access to this article
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Antoni, S. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol. 71, 96–108 (2017).
Boormans, J. L. & Zwarthoff, E. C. Limited funds for bladder cancer research and what can we do about it. Bladder Cancer 2, 49–51 (2016).
Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547–1557 (2020).
Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931–945 (2021).
Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25–41 (2015).
Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174–186 (2020).
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).
Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669–682 (2015).
Ho, P. L., Kurtova, A. & Chan, K. S. Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat. Rev. Urol. 9, 583–594 (2012).
Gabella, G. Lamina propria: the connective tissue of rat urinary bladder mucosa. Neurourol. Urodyn. 38, 2093–2103 (2019).
Gevaert, T. et al. Identification of different phenotypes of interstitial cells in the upper and deep lamina propria of the human bladder dome. J. Urol. 192, 1555–1563 (2014).
Neuhaus, J. et al. 3D-electron microscopic characterization of interstitial cells in the human bladder upper lamina propria. Neurourol. Urodyn. 37, 89–98 (2018).
Kuijpers, K. A. J., Heesakkers, J. P. F. A., Jansen, C. F. J. & Schalken, J. A. Cadherin-11 is expressed in detrusor smooth muscle cells and myofibroblasts of normal human bladder. Eur. Urol. 52, 1213–1221 (2007).
McCloskey, K. D. Interstitial cells in the urinary bladder — localization and function. Neurourol. Urodyn. 9, 82–87 (2010).
Baskin, L. S. et al. Cellular signaling in the bladder. Front. Biosci. 2, d592–d595 (1997).
Shin, K. et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472, 110–114 (2011).
Shin, K. et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26, 521–533 (2014).
Flier, J. S., Underhill, L. H. & Dvorak, H. F. Tumors: wounds that do not heal. N. Engl. J. Med. 315, 1650–1659 (1986).
Liebert, M., Washington, R., Wedemeyer, G., Carey, T. E. & Grossman, H. B. Loss of co-localization of alpha 6 beta 4 integrin and collagen VII in bladder cancer. Am. J. Pathol. 144, 787–795 (1994).
Paget, S. The distribution of secondary growths in cancer of the breast. Lancet 133, 571–573 (1889).
Lee, Y.-C. et al. Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. Nat. Commun. 10, 2131 (2019).
Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309–322 (2012).
Egeblad, M., Nakasone, E. S. & Werb, Z. Tumors as organs: complex tissues that interface with the entire organism. Dev. Cell 18, 884–901 (2010).
Junttila, M. R. & de Sauvage, F. J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501, 346–354 (2013).
Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337 (2004).
Sleeman, J. P. The metastatic niche and stromal progression. Cancer Metastasis Rev. 31, 429–440 (2012).
Ji, Q. et al. Primary tumors release ITGBL1-rich extracellular vesicles to promote distal metastatic tumor growth through fibroblast-niche formation. Nat. Commun. 11, 1211 (2020).
Peinado, H. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer 17, 302–317 (2017).
Duda, D. G. et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA 107, 21677–21682 (2010).
Krall, J. A. et al. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci. Transl Med. 10, eaan3464 (2018).
Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209–213 (2015).
Chan, K. S. Molecular pathways: targeting cancer stem cells awakened by chemotherapy to abrogate tumor repopulation. Clin. Cancer Res. 22, 802–806 (2016).
Panigrahy, D. et al. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. J. Clin. Invest. 129, 2964–2979 (2019).
Tuxhorn, J. A. et al. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 8, 2912–2923 (2002).
Toullec, A. et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol. Med. 2, 211–230 (2010).
Nielsen, S. R. et al. Corrigendum: macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. Nat. Cell Biol. 18, 822 (2016).
Albrengues, J. et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat. Commun. 6, 10204 (2015).
Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582–598 (2016).
Kojima, Y. et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl Acad. Sci. USA 107, 20009–20014 (2010).
Arina, A. et al. Tumor-associated fibroblasts predominantly come from local and not circulating precursors. Proc. Natl Acad. Sci. USA 113, 7551–7556 (2016).
Jung, Y. et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat. Commun. 4, 1795 (2013).
Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257–272 (2011).
McDonald, L. T. et al. Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia 17, 434–448 (2015).
Nimphius, W., Moll, R., Olbert, P., Ramaswamy, A. & Barth, P. J. CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder. Virchows Arch. 450, 179–185 (2007).
Bellini, A. & Mattoli, S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest. 87, 858–870 (2007).
Reilkoff, R. A., Bucala, R. & Herzog, E. L. Fibrocytes: emerging effector cells in chronic inflammation. Nat. Rev. Immunol. 11, 427–435 (2011).
Iwano, M. et al. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110, 341–350 (2002).
Zeisberg, M. et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J. Biol. Chem. 282, 23337–23347 (2007).
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M. & Kalluri, R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 67, 10123–10128 (2007).
Brunner, A. et al. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer. J. Clin. Pathol. 57, 927–931 (2004).
Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392–401 (2006).
Shiga, K. et al. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers 7, 2443–2458 (2015).
Mezheyeuski, A. et al. Fibroblasts in urothelial bladder cancer define stroma phenotypes that are associated with clinical outcome. Sci. Rep. 10, 281 (2020).
Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102–1123 (2019).
Helms, E., Onate, M. K. & Sherman, M. H. Fibroblast heterogeneity in the pancreatic tumor microenvironment. Cancer Discov. 10, 648–656 (2020).
Chen, Z. et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat. Commun. 11, 5077 (2020).
Hung, T.-T., Wang, H., Kingsley, E. A., Risbridger, G. P. & Russell, P. J. Molecular profiling of bladder cancer: involvement of the TGF-beta pathway in bladder cancer progression. Cancer Lett. 265, 27–38 (2008).
Liang, Y. et al. Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model. Sci. Rep. 6, 29479 (2016).
Wang, P. et al. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology 69, 780–784 (2007).
Szarvas, T., Vom Dorp, F., Ergün, S. & Rübben, H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat. Rev. Urol. 8, 241–254 (2011).
Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544–548 (2018).
Calvete, J. et al. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder. Hum. Pathol. 91, 61–68 (2019).
Park, J. E. et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 274, 36505–36512 (1999).
Hotary, K. B. et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 114, 33–45 (2003).
Feinberg, T. Y. et al. Divergent matrix-remodeling strategies distinguish developmental from neoplastic mammary epithelial cell invasion programs. Dev. Cell 47, 145–160.e6 (2018).
Hashitani, H., Mitsui, R., Shimizu, Y., Higashi, R. & Nakamura, K. Functional and morphological properties of pericytes in suburothelial venules of the mouse bladder. Br. J. Pharmacol. 167, 1723–1736 (2012).
Hashitani, H., Mitsui, R., Miwa-Nishimura, K. & Lam, M. Role of capillary pericytes in the integration of spontaneous Ca2+ transients in the suburothelial microvasculature in situ of the mouse bladder. J. Physiol. 596, 3531–3552 (2018).
Miodoński, A. J. & Litwin, J. A. Microvascular architecture of the human urinary bladder wall: a corrosion casting study. Anat. Rec. 254, 375–381 (1999).
Sherwood, L. M., Parris, E. E. & Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Risau, W. Mechanisms of angiogenesis. Nature 386, 671–674 (1997).
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S. & Reynolds, A. R. Vessel co-option in cancer. Nat. Rev. Clin. Oncol. 16, 469–493 (2019).
Patel, N. S. et al. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res. 12, 4836–4844 (2006).
McDonald, D. M. & Baluk, P. Significance of blood vessel leakiness in cancer. Cancer Res. 62, 5381–5385 (2002).
John, A. et al. Urothelial carcinoma of the bladder induces endothelial cell activation and hypercoagulation. Mol. Cancer Res. 18, 1099–1109 (2020).
Trédan, O., Galmarini, C. M., Patel, K. & Tannock, I. F. Drug resistance and the solid tumor microenvironment. J. Natl Cancer Inst. 99, 1441–1454 (2007).
Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284 (2015).
Ingersoll, M. A. & Albert, M. L. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol. 6, 1041–1053 (2013).
Abraham, S. N. & Miao, Y. The nature of immune responses to urinary tract infections. Nat. Rev. Immunol. 15, 655–663 (2015).
Gardiner, R. A. et al. Immunohistochemical analysis of the human bladder. Br. J. Urol. 58, 19–25 (1986).
Hart, D. N. J. & Fabre, J. W. Demonstration and characterization of ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J. Exp. Med. 154, 347–361 (1981).
Schilling, J. D., Martin, S. M., Hung, C. S., Lorenz, R. G. & Hultgren, S. J. Toll-like receptor 4 on stromal and hematopoietic cells mediates innate resistance to uropathogenic Escherichia coli. Proc. Natl Acad. Sci. USA 100, 4203–4208 (2003).
Engel, D. R. et al. CCR2 mediates homeostatic and inflammatory release of Gr1 high monocytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection. J. Immunol. 181, 5579–5586 (2008).
Mariano, L. L. et al. Functionally distinct resident macrophage subsets differentially shape responses to infection in the bladder. Sci. Adv. 6, eabc5739 (2020).
Christmas, T. J. Lymphocyte sub-populations in the bladder wall in normal bladder, bacterial cystitis and interstitial cystitis. Br. J. Urol. 73, 508–515 (1994).
Pettenati, C. & Ingersoll, M. A. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat. Rev. Urol. 15, 615–625 (2018).
Lobo, N. et al. 100 years of Bacillus Calmette–Guérin immunotherapy: from cattle to COVID-19. Nat. Rev. Urol. 18, 611–622 (2021).
Schneider, A. K., Chevalier, M. F. & Derré, L. The multifaceted immune regulation of bladder cancer. Nat. Rev. Urol. 16, 613–630 (2019).
Mo, Q. et al. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas. J. Natl Cancer Inst. 110, 448–459 (2018).
Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420–433 (2020).
Pfannstiel, C. et al. The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes. Cancer Immunol. Res. 7, 923–938 (2019).
Luo, Y., Zeng, G. & Wu, S. Identification of microenvironment-related prognostic genes in bladder cancer based on gene expression profile. Front. Genet. 10, 1187 (2019).
Daher, N., Abourachid, H., Bove, N., Petit, J. & Burtin, P. Collagen IV staining pattern in bladder carcinomas: relationship to prognosis. Br. J. Cancer 55, 665–671 (1987).
Sathyanarayana, U. G. et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 64, 1425–1430 (2004).
Naba, A. et al. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol. Cell. Proteom. 11, M111.014647 (2012).
Hynes, R. O. & Naba, A. Overview of the matrisome-an inventory of extracellular matrix constituents and functions. Cold Spring Harb. Perspect. Biol. 4, a004903 (2012).
Chaudhuri, O., Cooper-White, J., Janmey, P. A., Mooney, D. J. & Shenoy, V. B. Effects of extracellular matrix viscoelasticity on cellular behaviour. Nature 584, 535–546 (2020).
Said, N., Frierson, H. F., Sanchez-Carbayo, M., Brekken, R. A. & Theodorescu, D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J. Clin. Invest. 123, 751–766 (2013).
Yamauchi, M. & Sricholpech, M. Lysine post-translational modifications of collagen. Essays Biochem. 52, 113–133 (2012).
Chen, Y. et al. Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stroma. J. Clin. Invest. 125, 1147–1162 (2015).
Yamauchi, M., Barker, T. H., Gibbons, D. L. & Kurie, J. M. The fibrotic tumor stroma. J. Clin. Invest. 128, 16–25 (2018).
Levental, K. R. et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906 (2009).
Brooks, M. et al. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget 7, 82609–82619 (2016).
Reiser, K. M., Amigable, M. & Last, J. A. Nonenzymatic glycation of type I collagen. J. Biol. Chem. 267, 24207–24216 (1992).
American Cancer Society. Key statistics for bladder cancer. cancer.org https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html (2022).
Knight, C. G. et al. The collagen-binding a-domains of integrins α1/β1 and α2/β1 recognize the same specific amino acid sequence, GFOGER, in native (triple- helical) collagens. J. Biol. Chem. 275, 35–40 (2000).
Emsley, J., Knight, C. G., Farndale, R. W., Barnes, M. J. & Liddington, R. C. Structural basis of collagen recognition by integrin α2β1. Cell 101, 47–56 (2000).
Ichikawa, O. et al. Structural basis of the collagen-binding mode of discoidin domain receptor 2. EMBO J. 26, 4168–4176 (2007).
Xu, H. et al. Collagen binding specificity of the discoidin domain receptors: binding sites on collagens II and III and molecular determinants for collagen IV recognition by DDR1. Matrix Biol. 30, 16–26 (2011).
Aitken, K. J. & Bägli, D. J. The bladder extracellular matrix. Part I: architecture, development and disease. Nat. Rev. Urol. 6, 596–611 (2009).
Wilson, C. B., Leopard, J., Cheresh, D. A. & Nakamura, R. M. Extracellular matrix and integrin composition of the normal bladder wall. World J. Urol. 14 (Suppl. 1), S30–S37 (1996).
Ioachim, E. et al. A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int. 95, 655–659 (2005).
Eisinger, F., Patzelt, J. & Langer, H. F. The platelet response to tissue injury. Front. Med. 5, 317 (2018).
Rousselle, P., Montmasson, M. & Garnier, C. Extracellular matrix contribution to skin wound re-epithelialization. Matrix Biol. 75–76, 12–26 (2019).
Rohani, M. G. et al. MMP-10 regulates collagenolytic activity of alternatively activated resident macrophages. J. Invest. Dermatol. 135, 2377–2384 (2015).
Rohani, M. G. & Parks, W. C. Matrix remodeling by MMPs during wound repair. Matrix Biol. 44–46, 113–121 (2015).
Tu, M. M. et al. Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci. Adv. 5, eaav2437 (2019).
Zhuang, J. et al. TGFβ1 secreted by cancer-associated fibroblasts induces epithelial-mesenchymal transition of bladder cancer cells through lncRNA-ZEB2NAT. Sci. Rep. 5, 11924 (2015).
Goulet, C. R. et al. Exosomes induce fibroblast differentiation into cancer-associated fibroblasts through TGFβ signaling. Mol. Cancer Res. 16, 1196–1204 (2018).
Yan, L., Wang, P., Fang, W. & Liang, C. Cancer-associated fibroblasts-derived exosomes-mediated transfer of LINC00355 regulates bladder cancer cell proliferation and invasion. Cell Biochem. Funct. 38, 257–265 (2020).
Joseph, M. & Enting, D. Immune responses in bladder cancer — role of immune cell populations prognostic factors and therapeutic implications. Front. Oncol. 9, 1270 (2019).
Kawanishi, H. et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin. Cancer Res. 14, 2579–2587 (2008).
Miyake, M. et al. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia 18, 636–646 (2016).
Said, N., Sanchez-Carbayo, M., Smith, S. C. & Theodorescu, D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Invest. 122, 1503–1518 (2012).
Chu, M. & Zhang, C. Inhibition of angiogenesis by leflunomide via targeting the soluble ephrin-A1/EphA2 system in bladder cancer. Sci. Rep. 8, 1539 (2018).
Huang, Z. et al. Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression. Int. J. Oncol. 54, 1555–1566 (2019).
Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490–1499 (2016).
Winters, B. R. Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy. JCI Insight 4, e128728 (2019).
Goodison, S. et al. A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. J. Transl Med. 14, 287 (2016).
Shimizu, Y. et al. A multiplex immunoassay for the non-invasive detection of bladder cancer. J. Transl Med. 14, 31 (2016).
Arici, A. et al. Interleukin-8 induces proliferation of endometrial stromal cells: a potential autocrine growth factor. J. Clin. Endocrinol. Metab. 83, 1201–1205 (1998).
O’Connell, J. T. et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc. Natl Acad. Sci. USA 108, 16002–16007 (2011).
Lu, P., Takai, K., Weaver, V. M. & Werb, Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 3, a005058 (2011).
Tashiro, Y. et al. Inhibition of PAI-1 induces neutrophil-driven neoangiogenesis and promotes tissue regeneration via production of angiocrine factors in mice. Blood 119, 6382–6393 (2012).
Bancroft, C. C. et al. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-κB signal pathways. Clin. Cancer Res. 7, 435–442 (2001).
Metheny-Barlow, L. J. & Li, L. Y. The enigmatic role of angiopoietin-1 in tumor angiogenesis. Cell Res. 13, 309–317 (2003).
Zhang, G. et al. Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagn. Pathol. 9, 200 (2014).
Furuya, H. et al. Prognostic significance of lymphocyte infiltration and a stromal immunostaining of a bladder cancer associated diagnostic panel in urothelial carcinoma. Diagnostics 10, 14 (2019).
Chen, P. et al. MMP7 shedding of syndecan-1 facilitates re-epithelialization by affecting α2β1 integrin activation. PLoS ONE 4, e6565 (2009).
Miyake, M. et al. Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer. BMC Cancer 14, 86 (2014).
Wong, Y. N. S. et al. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. J. Exp. Med. 215, 2748–2759 (2018).
Volkmer, J. P. et al. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc. Natl Acad. Sci. USA 109, 2078–2083 (2012).
Wu, J. et al. Effects of increased Kindlin-2 expression in bladder cancer stromal fibroblasts. Oncotarget 8, 50692–50703 (2017).
Zhu, H., Chen, H., Wang, J., Zhou, L. & Liu, S. Collagen stiffness promoted non-muscle-invasive bladder cancer progression to muscle-invasive bladder cancer. Onco Targets Ther. 12, 3441–3457 (2019).
Chan, K. S. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106, 14016–1421 (2009).
Szarvas, T. et al. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum. Pathol. 45, 674–682 (2014).
Lodillinsky, C. et al. Bacillus Calmette Guerin induces fibroblast activation both directly and through macrophages in a mouse bladder cancer model. PLoS ONE 5, e13571 (2010).
Wang, L. et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat. Commun. 9, 3503 (2018).
van Puffelen, J. H. et al. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer. Nat. Rev. Urol. 17, 513–525 (2020).
Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. & Catalona, W. J. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150, 1018–1023 (1993).
Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389, 67–76 (2017).
[No authors listed.] Nod for atezolizumab in advanced bladder cancer. Cancer Discov. 7, OF4 (2017).
Inman, B. A., Longo, T. A., Ramalingam, S. & Harrison, M. R. Atezolizumab: a PD-L1-blocking antibody for bladder cancer. Clin. Cancer Res. 23, 1886–1890 (2017).
Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).
Powles, T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391, 748–757 (2018).
Wolf, M. T. et al. A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy. Sci. Transl Med. 11, eaat7973 (2019).
Nguyen, D. P. & Thalmann, G. N. Contemporary update on neoadjuvant therapy for bladder cancer. Nat. Rev. Urol. 14, 348–358 (2017).
Long, X. et al. Cancer-associated fibroblasts promote cisplatin resistance in bladder cancer cells by increasing IGF-1/ERβ/Bcl-2 signalling. Cell Death Dis. 10, 375 (2019).
Winters, B. R. et al. Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. Urol. Oncol. 36, 342.e7–342.e14 (2018).
Efstathiou, J. A. et al. Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer. Eur. Urol. 76, 59–68 (2019).
Taber, A. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 11, 4858 (2020).
Hayashi, K. et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat. Commun. 11, 6299 (2020).
Nikolos, F. et al. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed tumors. Nat. Commun. 13, 1487 (2022).
O’Keeffe, M. B. et al. Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol. Res. 17, 93–101 (2008).
Dyrskjot, L. et al. Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br. J. Cancer 107, 1392–1398 (2012).
Dyrskjøt, L. et al. Prognostic impact of a 12-gene progression score in non-muscle-invasive bladder cancer: a prospective multicentre validation study. Eur. Urol. 72, 461–469 (2017).
The authors declare no competing interests.
Peer review information
Nature Reviews Urology thanks Lars Dyrskjøt, François Radvanyi and Edmund Chiong for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lee, YC., Lam, HM., Rosser, C. et al. The dynamic roles of the bladder tumour microenvironment. Nat Rev Urol (2022). https://doi.org/10.1038/s41585-022-00608-y